ClearPoint Neuro Q2 FY26 net loss widens to $11.34 million; revenue rises 18% to $10.9 million
CLPT•Q2 results
ClearPoint Neuro posted Q2 revenue of $10.9 million, up 18% year over year; gross margin rose 2 percentage points to 62%.
Net loss widened to $11.34 million, or $0.38 per share, from $5.84 million, or $0.21 per share, a year earlier.
Operating loss expanded to $10.24 million from $5.68 million; operating expenses climbed 51% to $17 million, driven by the IRRAS acquisition.
Segment performance and guidance
Biologics and drug delivery revenue fell 15% to $4 million on lower biopharma trial-initiation shipments; neurosurgery navigation and therapy revenue jumped 62% to $5.6 million.
ClearPoint cut 2026 revenue guidance to $48 million-$52 million, citing increased investment in clinical capacity, CAL expansion, focused ultrasound, robotics, and Harmony software.
